Curriculum Vitae:

Is a Professor of Medicine at the MD Anderson Cancer Center in Houston, USA. Dr. Burger received his M.D./Ph.D. degree at Albert-Ludwigs-University in Freiburg, Germany, with subsequent clinical training and board certification in Internal Medicine and Hematology/Oncology at Freiburg University Hospital, before moving to MD Anderson in 2005. In 2006, Dr. Burger received the “Venia legendi” (Habilitation) for Internal Medicine at Albert-Ludwigs-University in Freiburg. Moreover, from 1996 to 1999, Dr. Burger received postdoctoral research training in Hematology and Immunology at the University of California, San Diego. As a clinical and laboratory investigator, Dr. Burger focuses on developing new therapeutic approaches for targeting the microenvironment in chronic lymphocytic leukemia (CLL), other B cell malignancies, and acute leukemias. Laboratory research by Dr. Burger’s group characterized B cell receptor (BCR)-associated kinases, such as BTK and PI3 kinases, as therapeutic targets. Dr. Burger serves as a principal investigator on clinical trials which explore these targets in CLL, and has been leading key trials that supported the approval of the BTK inhibitor ibrutinib (Resonate 2: ibrutinib for CLL frontline therapy). For his innovative research, Dr. Burger received several awards, among them, the Arthur Pappenheim Award by the DGHO, a Kimmel Scholar Award, ASCO Young Investigator and Career Development awards, the Leukemia and Lymphoma Society Scholar award, and the MD Anderson Faculty Scholar Award. Dr. Burger is a regular speaker at EHA and ASH, and has published in the leading Journals in his field.

Curriculum Vitae:

Médica hematóloga, diplomada en trasplante de MO.
Cargos: Hematóloga en Unidad de hematología y trasplante de MO del Hospital Británico.
Hematóloga en CASMU.
Miembro del Grupo Uruguayo de LLC, Grupo Uruguayo de Linfoma, GELL, ASH y EHA.

Curriculum Vitae:

Is a scientist with a strong focus on Immunology, Hematology, and Oncology.
He heads the Research Laboratory on Chronic Lymphocytic Leukemia (CLL) at the Pasteur Institute of Montevideo.
Dr. Oppezzo has participated in different national and international scientific committees in the field of CLL and coordinated the first project aimed at generating a CLL network in the region through the Ibero-American Program for Science and Technology for Development (CYTED).
He has published more than 60 articles, most of them focused on CLL prognosis and the role of the tumor microenvironment in the progression of B-cell malignancies

Curriculum Vitae:

Martina Seiffert is a group leader at the German Cancer Research Center in Heidelberg. She is interested in immune modulatory mechanisms in the tumor microenvironment, with a focus on chronic lymphocytic leukemia. Using innovative single-cell omics approaches and functional studies with primary cell culture and mouse models, her team deciphers mechanisms of immune suppression and T-cell dysfunction and develops novel immunotherapies.

Curriculum Vitae:

Name: Pablo Muxí
Academic training:
- Medical Doctor, specialist in Internal Medicine and Hematology
- Bachelor's Degree: Hematopoietic Stem Transplantation
Teaching Position:
Professor, Director of the British Hospital Hematology Postgraduate Course – CLAEH Faculty of Medicine
Assistance Charges:
Director of the Hematology and Hematopoietic SCT Unit, British Hospital. Uruguay
Others
Fulbright Scholar at Montefiore Medical Center Hospital in Bronx NYC 1993-1994.
National Grand Prize in Medicine – National Academy of Medicine. 2012
Scientific Committee World Congress of the International Society of Hematology 2007
Full Member of the National Academy of Medicine. 2013
Editorial Board: Journal of Clinical Oncology: 2013-2019

Curriculum Vitae:

Dr. Palacios is an Assistant Professor at the Institut Pasteur Montevideo, Uruguay, specializing in cancer immunology. She completed her Ph.D. focusing on chronic lymphocytic leukemia (CLL) under the mentorship of Prof. Dighiero and Dr. Oppezzo at the Institut Pasteur Montevideo. Following her Ph.D., she pursued postdoctoral research with Prof. Chiorazzi, MD, and Prof. Rai, MD, at The Feinstein Institutes for Medical Research in the United States, where she investigated the intraclonal complexity of B cells and its impact on the progression of CLL. In 2021, Dr. Palacios returned to Uruguay as an Assistant Professor at the Institut Pasteur Montevideo. Her research interests lie in translational medicine, with a particular focus on discovering new therapeutic targets and treatments.

Curriculum Vitae:

Médica hematóloga, diplomada en trasplante de MO.
Cargos: Hematóloga en Unidad de hematología y trasplante de MO del Hospital Británico.
Hematóloga en CASMU.
Miembro del Grupo Uruguayo de LLC, Grupo Uruguayo de Linfoma, GELL, ASH y EHA.

Curriculum Vitae:

Is a scientist with a strong focus on Immunology, Hematology, and Oncology.
He heads the Research Laboratory on Chronic Lymphocytic Leukemia (CLL) at the Pasteur Institute of Montevideo.
Dr. Oppezzo has participated in different national and international scientific committees in the field of CLL and coordinated the first project aimed at generating a CLL network in the region through the Ibero-American Program for Science and Technology for Development (CYTED).
He has published more than 60 articles, most of them focused on CLL prognosis and the role of the tumor microenvironment in the progression of B-cell malignancies

Curriculum Vitae:

Martina Seiffert is a group leader at the German Cancer Research Center in Heidelberg. She is interested in immune modulatory mechanisms in the tumor microenvironment, with a focus on chronic lymphocytic leukemia. Using innovative single-cell omics approaches and functional studies with primary cell culture and mouse models, her team deciphers mechanisms of immune suppression and T-cell dysfunction and develops novel immunotherapies.

Curriculum Vitae:

Former Head of Hematology at the Hospital General de Agudos CABA "Teodoro Álvarez" until 2022 and former head of the Division Hematology at Policlínico Bancario (1996-2013).
Active member of GATLA from 1974 to 2023. Coordinator for Argentina of GRELIC (2009-2011). Member of CLL LAG and chairman of the IBAM 2018 held in Buenos Aires.
Has published more than 75 papers in national and international journals and is co-author of more than 150 papers presented at national and international conferences.
He participated in the publication of 6 books related to CLL, Chronic Lymphoproliferative Disorders, and Chronic T Cell Leukemias. He has been co-authoring of the Diagnostic and Treatment Guidelines of the Argentine Society of Hematology since 2009.

Curriculum Vitae:

Is a Professor of Medicine at the MD Anderson Cancer Center in Houston, USA. Dr. Burger received his M.D./Ph.D. degree at Albert-Ludwigs-University in Freiburg, Germany, with subsequent clinical training and board certification in Internal Medicine and Hematology/Oncology at Freiburg University Hospital, before moving to MD Anderson in 2005. In 2006, Dr. Burger received the “Venia legendi” (Habilitation) for Internal Medicine at Albert-Ludwigs-University in Freiburg. Moreover, from 1996 to 1999, Dr. Burger received postdoctoral research training in Hematology and Immunology at the University of California, San Diego. As a clinical and laboratory investigator, Dr. Burger focuses on developing new therapeutic approaches for targeting the microenvironment in chronic lymphocytic leukemia (CLL), other B cell malignancies, and acute leukemias. Laboratory research by Dr. Burger’s group characterized B cell receptor (BCR)-associated kinases, such as BTK and PI3 kinases, as therapeutic targets. Dr. Burger serves as a principal investigator on clinical trials which explore these targets in CLL, and has been leading key trials that supported the approval of the BTK inhibitor ibrutinib (Resonate 2: ibrutinib for CLL frontline therapy). For his innovative research, Dr. Burger received several awards, among them, the Arthur Pappenheim Award by the DGHO, a Kimmel Scholar Award, ASCO Young Investigator and Career Development awards, the Leukemia and Lymphoma Society Scholar award, and the MD Anderson Faculty Scholar Award. Dr. Burger is a regular speaker at EHA and ASH, and has published in the leading Journals in his field.

Curriculum Vitae:

Romina Gamberale, Ph.D., is currently Director of the Institute of Experimental Medicine (IMEX)-CONICET at the National Academy of Medicine in Buenos Aires, Argentina and Co-Director of the Laboratory of Onco-Immunology (https://imex.conicet.gov.ar/ ). She attended University of Buenos Aires where she majored in Cellular Biology in 1998 and received her Ph.D. in Cellular Biology in 2002 at the University of Buenos Aires studying the role of the microenvironment in Chronic Lymphocytic Leukemia (CLL) under the mentorship of Dr. Mirta Giordano. She obtained a fellowship of the French Society of Cancer to attend to Marie Curie Institute in Paris in 2001 to study the role of the tyrosine kinase Syk in dendritic cell maturation, under the supervision of Dr. Sebastian Amigorena. Then, in 2003 she obtained another research fellow to study the mutational status of CLL patients in the Pasteur Institute in Paris under the supervision of Dr. Guillermo Dighiero. She has been teaching Immunology at the School of Medicine at the University of Buenos Aires since 1998 and she is the co-Coordinator of the Immunology Course in the Hematologist Training Program of the Argentinian Society of Hematology since 2015. Her research group is interested in studying how the tumor microenvironment regulates the activation, proliferation and survival of CLL cells and their response to different therapeutic agents. Dr. Gamberale actively fosters the promotion of regional development of basic and clinical research in LLC. She participates in the Latin American Group of CLL (LAG-CLL) and also participates in the iwCLL Global Partnerships Subcommittee, a working subcommittee of international leaders in CLL whose objective is to improve the situation of CLL patients worldwide, promoting clinical and/or research training of hematologists/investigators, improving local research capacities, training of future academic leaders in CLL research, and CLL awareness among patients all over the world (https://www.iwcll.org/about/subcommittee/global-partnerships-subcommittee/).
Throughout his career, she has supervised the research of numerous undergraduate fellows, Ph.D students, post-docs and young investigators interested in CLL and publishes more than 50 papers in immunology and hematology international journals.